We recommend yearly ophthalmologic investigation and yearly cardiovascular risk management screening including blood pressure, lipids, glucose, insulin, liver function, urine albumin-to-creatinine ratio, ultrasound and fibroscan of the liver.
When the diabetes mellitus and lipodystrophy are therapy resistant, we recommend to measure leptin levels and consider treatment with metraleptin [Fourman, 2024, PMID 38952397].
POC5